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Background: Treatment options for women presenting with triple negative breast cancer (TNBC) are limited due
to the lack of a therapeutic target and as a result, are managed with standard chemotherapy such as paclitaxel
(Taxol®).
Following chemotherapy, the ideal tumour response is apoptotic cell death. Post-chemotherapy, cells can main-
tain viability by undergoing viable cellular responses such as cellular senescence, generating secretomes which
can directly enhance the malignant phenotype.
Scope of Review: How tumour cells retain viability in response to chemotherapeutic engagement is discussed. In
addition we discuss the implications of this retained tumour cell viability in the context of the development of
recurrent and metastatic TNBC disease.
Current adjuvant and neo-adjuvant treatments available and the novel potential therapies that are being
researched are also reviewed.
Major conclusions: Cellular senescence and cytoprotective autophagy are potential mechanisms of
chemoresistance in TNBC. These two non-apoptotic outcomes in response to chemotherapy are inextricably
linked and are neglected outcomes of investigation in the chemotherapeutic arena. Cellular fate assessments
may therefore have the potential to predict TNBC patient outcome.
General Signiﬁcance: Focusing on the fact that cancer cells can bypass the desired cellular apoptotic response to
chemotherapy through cellular senescence and cytoprotective autophagy will highlight the importance of
targeting non-apoptotic survival pathways to enhance chemotherapeutic efﬁcacy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Triple negative breast cancers (TNBCs) are a speciﬁc subtype of epi-
thelial breast tumours that are immunohistochemically negative for the
protein expression of the oestrogen receptor (ER), the progesterone
receptor (PR) and lack overexpression/gene ampliﬁcation of HER2 [1].
Approximately, 10–14% of breast cancers are triple negative and the
methods used to perform a diagnosis generally dictate the frequency
[2]. Pre-analytic and analytic issues such as delay from tissue collection
to ﬁxation (risk of cold ischemia) and assay reproducibility (assay
validation and standardisation) can impact on whether a tumour is
assigned as Triple Negative or not [3].
1.1. Immunohistochemical testing
The characterisation and measurement of the oestrogen receptor
(ER) protein was ﬁrst described by Jensen et al., in 1967 and in 1973,
McGuire et al., described the dextran-coated charcoal (DCC) biochemi-
cal assay to quantify the ER protein [4,5]. It was also then postulated
that detection of the oestrogen receptor may predict response to endo-
crine therapy. Immunohistochemical (IHC) methodologies have been
used since the early 1990s and remain by far the most common type
of assay worldwide. However, there is an inadequate standardisation
of the IHCmethodology. A recent “ring study” showed an initial ER test-
ing concordance between two central laboratories at just 85%, which
was fully resolved once both laboratories adopted the same ER assay
methods [6].
Recent misclassiﬁcation (false negative) reports have raised aware-
ness concerning the limitations of immunohistochemistry (IHC) in the
assessment of the oestrogen receptor (ER) in breast cancer. Hede et al.
(2008) describe the incident in Canada where there was a 40% misclas-
siﬁcation rate between local and central laboratories highlighting the
current limitations associated with ER protein testing [7].
Rimm et al., 2011 describe a potential method for standardising ER
measurement “on a slide” using a quantitative immunoﬂuorescence
(QIF) assay [8]. Moreover, Rimm’s data also show that an assessment
of the intensity threshold by using this assay on two independent co-
horts resulted in discordance in the 10% to 20% range with current IHC
methods. Overall, the ﬁndings of the study were that (a) the threshold
of immunoreactivity appears to bemore important than the percentage
positivity in the generation of discordant or false-negative assays and
that (b) the standardisation method by using the QIF assay appeared
to be more sensitive than the traditional IHC assay. This was despite
the fact that the same antibody was used for the detection of ER
(1D5). Rimm et al., concluded that (a) intensity threshold, in other
words, what actually constitutes a “positive” nucleus is the key determi-
nant of variable scoring that needs to be controlled to correctly deﬁne
ER characterisation and that (b) the QIF assay is more sensitive than
routine IHC [8].
The American Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) issued guidelines to address this issue of dis-
cordance in ER assessment. An IHC cutoff of 1% positive nuclei is now
used to deﬁne a tumour as ER positive compared to the previous cut
off of 10% positive nuclei [9]. Few ER-positive tumours have true IHC
staining between 1% and 10% [10]. However, false-negative ER results
can still occur even when using a validated and reproducible IHC assay
and an imaging analysis system is unlikely to improve detection of
tumours with low levels of ER. This justiﬁes the use of a low IHC cutoff
(1%) for clinical use to minimise this risk of false-negative ER. In the
absence of a linear correlation between ER expression by IHC and
clinical outcome, available data suggest that a qualitative assessment
(ER positive v ER negative) is more critical than a quantitative IHC
assay [3].
Accurate testing for the HER2/neu gene overexpression is also an
issue where false-positives using IHC can occur. In 1999, Jacobs et al.,
highlighted this with the HercepTest, where tumours identiﬁed as
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HER2 positive by this test were subsequently described as negative
using FISH and other IHC methods using the same antibody [11]. The
"gold standard" used to identify these false-positive results has
been tested for HER2/neu gene ampliﬁcation by FISH. This is due to
the greater speciﬁcity and sensitivity of FISH when either test is
compared with HER2/neu overexpression as determined by Northern
and Western blot analyses [12,13].
Studies have also shown that the problem of false-positive HER2
results, involve IHC techniques most signiﬁcantly when the result is
2+ [14]. Speciﬁcally, as few as 17% of 2+ HercepTest carcinomas dem-
onstrate gene ampliﬁcation by FISH [15]. The overwhelmingmajority of
3+ positives demonstrate HER2 gene ampliﬁcation. However, in a
study by Mass et al., 2000, 11% of 3+ positive tumours did not demon-
strate gene ampliﬁcation by FISH. This indicates that false-positive re-
sults are a potential problem in this group as well [16]. False-negative
results, in other words, IHC-negative/FISH-positive carcinomas, are
rare in the 0–1+ IHC groupings.
The ASCO and the College of American Pathologists (CAP) recently
updated HER2 testing guidelines to improve the accuracy of HER2 test-
ing and its utility as a predictive marker in invasive breast cancer [3]. A
systematic review was conducted to identify areas requiring clariﬁca-
tion and to improve the accuracy of HER2 testing by immunohisto-
chemistry (IHC) or in situ hybridisation (ISH). The guidelines have
been published jointly in the Journal of Clinical Oncology and the
Archives of Pathology & Laboratory Medicine. These recommendations
will improve the analytical validity of HER2 testing, its clinical utility
and the communication among health-care providers [17].
Recommendations include:
• That HER2 status (HER2 negative or positive) be determined in all
patients with invasive (early stage or recurrence) breast cancer on
the basis of one or more HER2 test results (negative, equivocal, or
positive).
• That testing criteria deﬁne HER2-positive status when there is
evidence of protein overexpression (IHC) or gene ampliﬁcation
(HER2 copy number or HER2/CEP17 ratio by ISH based on counting
at least 20 cells within the area).
• That if results are equivocal (revised criteria) reﬂex testing should be
performed using an alternative assay (IHC or ISH).
• That repeat testing should be considered if results seem discordant
with other histopathological ﬁndings.
• Those laboratories should demonstrate high concordance with a
validated HER2 test on a sufﬁciently large and representative set of
specimens.
• That HER2 testing must be performed in a laboratory accredited by
CAP or another accrediting entity.
1.2. Epidemiology
TNBC’s are typically of the histological ductal typewith a highmitot-
ic rate, increased lymphocytic inﬁltrate, high grade and large tumour
size. In addition, TNBC patients commonly present with early visceral
metastases and have lymph node involvement at the time of diagnosis
[18,19]. Approximately 15% of TNBC patients will develop brain metas-
tases with autopsy studies reporting a 30% rate [20]. This aggressive
metastatic cancer contributes to the overall shortened survival of
patients with TNBC [21].
In relation to age, TNBC’s affect younger women more frequently
and are more prevalent in African-Americans who are three times
more likely to present with TNBC than Caucasian women [22]. In fact
39% of all African American premenopausal women diagnosed with
breast cancer are diagnosed with TNBC [23]. The prevalence of TNBC
in this same age group in non–African American women is demonstra-
bly less approximating at 15%. These ethnic and/or menopausal
differences are not seen in either, the ER+/HER2+ breast cancer sub-
group or the ER+/HER2– subgroup [23]. Women presenting with
TNBC also have a higher rate of distant recurrence and a poorer progno-
sis thanwomenwith other subtypes of breast cancer. Paradoxically, this
higher rate of distant recurrence occurs despite these women having
initial higher response rates to neoadjuvant chemotherapy [24].
1.3. TNBC molecular and gene expression subtypes; a heterogenous cancer
As a result of gene expression proﬁling, breast cancer has been clas-
siﬁed into ﬁve distinct molecular subtypes, namely; normal-like, basal,
luminal A& B andHER-2 enriched [25]. A Claudin-low sub-type is anoth-
er described molecular subtype referring to tumours showing features
of mesenchymal and mammary stem cells [26]. Interestingly, tumour
cells that survive chemotherapy show features similar to mesenchymal
claudin-low tumour cells [27].
In relation to TNBC’s, 75% fall into the basal-subtype and express
genes normally associated with normal basal like myoepithelial cells
of the breast ductal and lobular system, such as the epidermal growth
factor receptor (EGFR) [28]. Basal-like breast cancers tend to express
cytokeratins associated with basal types of cancers, as they arise from
the outer basal layer. It has also been reported that almost 82% of basal-
like breast cancers express p53 compared with 13% in the luminal A sub-
group [29]. Useful immunohistochemicalmarkers for characterising basal
like carcinomas include CK5, CK6, CK14, CK8/CK18, p63, P-cadherin,
vimentin, epidermal growth factor receptor 1 (EGFR1), c-kit, and other
growth factors such as vascular-endothelial growth factor (VEGF) and
the insulin-like growth factor receptor (IGFR) [28].
Lehmann et al., 2011 have analysed the gene-expression proﬁles
from 21 breast cancer data sets of which 587 were TNBC [30]. Six
TNBC subtypes were shown to have unique gene expression proﬁles,
namely basal-like (BL1 & BL20), an immunomodulatory (IM), a mesen-
chymal (M), a mesenchymal stem-like (MSL) and a luminal androgen
receptor (LAR) subtype. Identiﬁcation of TNBC cell line models rep-
resentative of these subtypes was performed using further gene ex-
pression (GE) analysis. Predicted “driver” signalling pathways were
pharmacologically targeted in these cell line models as proof of
concept that the analysis of distinct GE signatures had the potential
to inform patient therapy decision.
In general, the BL1 and BL2 TNBC subtypes had higher expression of
cell cycle and DNA damage response genes. Moreover, representative
cell lines preferentially responded to cisplatin. In the M and MSL sub-
types, these were enriched in GE proﬁles representing the epithelial-
mesenchymal transition (EMT), and growth factor pathways with
cell models responding to NVP-BEZ235 (a PI3K/mTOR inhibitor) and
dasatinib (an abl/src inhibitor). The LAR subtype included patients
with a decreased relapse-free survival and was characterised by andro-
gen receptor (AR) signalling. LAR cell lines were uniquely sensitive to
the AR antagonist bicalutamide. To the future, the identiﬁcation and
characterisation of these diverse TNBC subtypes and the molecular
drivers in corresponding cell line models has the potential to provide
great insight into the heterogeneity of this disease and to provide
preclinical platforms for the development of effective treatment.
2. Adjuvant & neoadjuvant chemotherapy used in TNBC
It is well established that TNBC is an aggressive group of breast can-
cer subtypes despite having a good initial response to chemotherapy. It
is also well established that patients with residual TNBC disease post
neo-adjuvant chemotherapy have a worse prognosis than those pre-
senting with non-TNBC [2]. Importantly, there is no preferred standard
chemotherapy for these patients and typically tumour size, lymph node
status, grade, overall performance status and the presence or absence of
medical co-morbidities will determine the regimens used. For women
presenting with triple negative breast cancer (TNBC), it is established
that in the absence of ER, PR andHER-2, endocrine therapies such as Ta-
moxifen and aromatase inhibitors and HER-2 directed therapies such as
Trastazumab and Lapatinib are not efﬁcacious. Triple negative breast
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cancers seem to be particularly chemo-sensitive to anthracyclines and
taxanes which are part of the standard therapy used for high risk
patients, for example those patients with node positive disease. In
spite of this, however, there is an overall poorer survival [31].
Although TNBCs are generally very susceptible to chemotherapy
initially, early complete response (CR) does not correlate with overall
survival. Speciﬁcally, the risk of relapse for TNBC patients in the ﬁrst
3–5 years is signiﬁcantly higher than for women presenting with hor-
mone positive breast cancer [32,33]. Clinically, this makes it particularly
challenging to ﬁnd the optimal chemotherapy which will result in a
longer metastasis free and overall survival for these women.
Neoadjuvant chemotherapy is clinicallywheremost of the knowledge
about chemosensitivity has arisen. Speciﬁcally, there is a higher patholog-
ic complete response, (PCR) related to neoadjuvant anthracycline based
chemotherapy in TNBC compared to luminal non-TNBC subtypes. How-
ever, despite initial chemosensitivity, metastatic relapse paradoxically
appears to occur at higher rates for TNBC tumours [2].
In the adjuvant therapy space, the principles for nonTNBC apply
equally to TNBC. These therefore can include:-
1) Doxorubicin or Epirubicin (Anthracyclines)
2) AC (Doxorubicin and Cyclophosphamide)
3) Paclitaxel and Docetaxel (often weekly and often every third week
respectively), frequently used in combination with Cyclophosphos-
phamide or 5-Fluorouracil. For example, ACT (doxorubicin, cyclo-
phosphamide, paclitaxel), TC (docetaxel and cyclophosphamide),
TFEC (docetaxel, 5-Fluorouracil, epirubicin, cyclophosphamide)
4) CMF (cyclophosphamide, methotrexate, 5-Fluorouracil)
5) Antimetabolites such as Gemcitabine or Capecitabine and other
microtubule inhibitors or stabilisers such as Vinorelbine.
6) Non-taxane anti-tubulin agents such as Eribulin and Ixabepilone,
which are associated with limited clinical efﬁcacy in TNBC as
opposed to non-TNBC presentations.
3. Novel potential therapies for TNBC
TNBCs can arise in BRCA1mutation carriers and have gene expres-
sion proﬁles similar to those of BRCA1-deﬁcient tumours [19].
Moreover, BRCA1-associated breast cancer appears to cluster in the
basal-like subtype [34]. BRCA1 mutation carriers often display basal
like gene expression proﬁles, and there is increasing evidence that a
TNBC basal like subtype develops mainly through a BRCA1-related
pathway, resulting in increased genomic instability [35]. For BRCA1
mutation carriers, the incidence of TNBC approximates to 70% [36,37],
although the incidence of BRCA mutations in TNBC can vary from 16%
to 42% [38].
Even though a patient may lack the BRCA-1 somatic mutation,
sporadically arising basal-like cancers often display a dysfunctional
BRCA-1 pathway [39]. TNBC’s and BRCA1-deﬁcient tumours share
certain histological features including genomic instability, DNA repair
defects [39] and mutations in p53, which disrupt apoptosis and which
are associated with a poor prognosis [40]. Importantly, BRCA1 plays an
important role in DNA double-strand break repair, contributing to the
maintenance of DNA stability [41].
3.1. Poly ADP-ribose polymerase (PARP) inhibition
Poly ADP-ribose polymerase (PARP) enzymes are critical for the ap-
propriate processing and repair of DNA breaks [42]. Tumour cell lines
lacking functional BRCA1 or BRCA2 are sensitive to PARP inhibitors in
preclinical studies [43]. Clinical trials using both PARP inhibitors and
DNA-damaging agents in TNBC have shown some promising results in
BRCA1/2-mutant tumours [44]. Speciﬁcally, the PARP inhibitor olaparib
has been used in the treatment of patients with BRCA 1 and 2 deﬁcient
tumours: − cancers which share similar features to sporadic TNBC,
where some efﬁcacy has been shown in a Phase II trial in BRCA-
deﬁcient recurrent advanced breast cancers, with enrolled patients hav-
ing previously been given three previous chemotherapy regimens prior
to the trial. Clinically, the objective response rates were 41% (n = 11)
and 22% (n = 6) for patients receiving Olaparib 400 mg twice daily
and Olaparib 100 mg twice daily, respectively. Moreover, the median
progression-free survival in the 400 mg BD cohort was 5.7 months,
compared with 3.8 months in the 100 mg twice daily cohort [45,
46].However, clinical data from another similarly sized cohort of tu-
mours (n = 15) failed to demonstrate any response in BRCA
mutation-negative TNBC patients [47].
The PARP inhibitor Iniparib versus placebo with Gemcitabine and
Carboplatin has demonstrated signiﬁcant improvement in patients
with pre-treated TNBC with an overall response rate (ORR) of 52% ver-
sus 33%, progression free survival (PFS) of 5.9 versus 3.6 months and
overall survival (OS) of 12.3 versus 7.7 months [48]. However, results
of a multicentre, phase III trial assessing the same iniparib combination
in advanced TNBC failed to meet the primary study end points with
a PFS of 4.1 versus 5.1 months and overall survival of 11.1 versus
11.8 months [49].
The combination of Veliparib with the oral alkylating agent
temozolamide, resulted in an improved response, bearing in mind that
20% of the patients in this trial had BRCA germ linemutations. However,
this Phase II trial did not include a TNBC subgroup analysis [50].
Overall, PARP inhibitors have shown little beneﬁt in unselected
TNBC populations, either as a single regimen [46] or used in combina-
tion with other standard chemotherapeutics [51,52], although BRCA-
selected patient groups may potentially beneﬁt from ongoing PARP
development [53].
3.2. Platinum salts
Three randomised trials have investigated the clinical efﬁcacy of
using platinum based regimens for the treatment of TNBC, [54–56]
with further randomised trials evaluating the addition of platinumderiv-
atives to standard adjuvant therapy (NCT01150513 & NCT01216111).
NCR01378533 is an adjuvant phase III trial comparing a dose dense
anthracycline–taxane regimen to dose dense paclitaxel and carboplatin.
The combination of a platinum based agent with the PARP inhibitor
PF-01367338 is also currently being evaluated following preopera-
tive chemotherapy in patients with TNBC or BRCA1/2-associated BC
(NCT01074970).
In the metastatic and second line setting, the addition of cisplatin to
metronomic methotrexate and cyclophosphamide has resulted in an
improvement in the median time-to-progression (TTP) of 6 months
(from 7 to 13months) and OS of 4months (from 12 to 16months) [54].
Carey et al., 2008 have also shown that when carboplatin is added to
the single-agent cetuximab in pretreated advanced TNBC patients, the
overall response rate (ORR) is 17% versus 6% [55]. Cetuximab plus
carboplatin produced partial responses in 71% (13/18) patients com-
pared to cetuximab monotherapy; 2 (6) of 31% patients and stable
disease lasting ≥6 months in 6 additional patients (9%) [57].
However, the addition of cisplatin to the anthracycline-taxane based
regimen showed no improvement in pathological complete response
(pCR) rates or rates of breast conserving surgery in the basal like
TNBC cohort of patients enrolled in The Spanish Breast Cancer Research
Group (GEICAM) 2006 phase II RCT [56].
In phase II trials [56,58], the combination of weekly cisplatin
added to weekly epirubicin and paclitaxel, produced a pCR rate of 62%
and 5-year disease-free survival (DFS) andOS values of 76% and 89%, re-
spectively. In addition, Liu et al., 2013 have undertaken a meta analysis
of platinum-based chemotherapy in TNBC, which included 7 studies
and 717 patients of which 31% were TNBC [59]. These results showed
that in the neo-adjuvant setting, the clinical complete response (cCR)
rate and the pathological complete response (pCR) rates were signiﬁ-
cantly higher for the TNBC group compared with the non-TNBC group
(OR, 2.68; 95% CI, 1.69-6.57; p = 0.03 and OR, 2.89; 95% CI, 1.28, 6.53;
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p = 0.01, respectively). However, in advanced/metastatic breast can-
cers, the cCR, partial response (PR) and the disease control rates
for the TNBC group were not signiﬁcantly different compared with the
non-TNBC group. In the same study [59], the 6-month progression-
free survival (PFS) rate for the TNBC group was higher than that of the
non-TNBC group in all patients (OR, 1.81; 95% CI, 1.11-2.96; P = 0.02).
Nonetheless, the 1- and 2-year PFS rateswere not signiﬁcantly different
between the TNBC and non-TNBC group (OR, 1.42; 95% CI, 0.69-2.92;
P = 0.35 and OR, 1.11; 95% CI, 0.35-3.52; P = 0.85, respectively). Also,
there was no signiﬁcant difference in the PFS rates between the groups
in patients with advanced/metastatic breast cancer.
In summary, this meta-analysis demonstrated that in the neoadju-
vant setting, platinum-based chemotherapy in the TNBC group shows
short-term efﬁcacy comparedwith the non-TNBC group. Unfortunately,
no improvement in advanced TNBC was demonstrated [59].
The addition of platinum agents to anthracycline and/or taxane reg-
imens in the neoadjuvant setting has shown promising outcomes, with
pathological pCRs ranging from 30% to 62%. The results of the Phase II
CALGB/Alliance 40603 clinical trial which looked at the impact of the
addition of carboplatin and/or bevacizumab to neoadjuvant weekly
paclitaxel followed by dose-dense doxorubicin and cyclophosphamide
on pCR rates in TNBC were presented at the 2013 San Antonio Breast
Cancer symposium [60]. The addition of carboplatin to standard neoad-
juvant chemotherapy increased pCR. Despite increases in pCR with
bevacizumab, side effects were more concerning with this drug.
Pathologic complete response rates were 60% for patients receiving
carboplatin and 46% in patients who did not receive carboplatin; an
increase of 76% (P = .0018). Deﬁned by no disease in the breast or
axilla, pCR rates increased to 54% and 41%, respectively; a 71% increase
(P = .0029)
The addition of bevacizumab was also associated with an improve-
ment in pCR in the breast only, producing pCRs in 59% of patients receiv-
ing the drug and 48% of patients not treated with bevacizumab; a 58%
increase (P = 0.0089). Pathologic complete response rates for both
breast and axilla were 52% and 44%, respectively; a 36% nonsigniﬁcant
increase (P = .0570). When carboplatin and bevacizumab were used
in combination, the highest pCR rate of 67% was achieved. However,
the P value for the carboplatin/bevacizumab interaction was .52,
indicating a lack of a synergistic effect.
3.3. Microtubule stabilising agents
A review in 2012, focused on potential new treatments for TNBC and
included the microtubule-stabilising agent, ixabepilone [61]. Clinical
trials have shown that when used with capecitabine (a second-line ther-
apy widely used in anthracycline and taxane-resistant disease),
ixabepilone has an acceptable safety proﬁle and clinical activity, when
comparedwith capecitabine alone. Thewomen in this trial had locally ad-
vanced or metastatic cancer, pre-treated with an anthracycline and a
taxane [62,63]. Analysis of pooled data from these trials found that the
overall response rate (ORR) (31 vs. 15%) and progression free survival
(PFS) (4.2 vs. 1.7months), were improved forwomenwith TNBCwho re-
ceived combination therapy of ixabepilone and capecitabine as opposed
to those women who received single-agent capecitabine alone [64].
3.4. Angiogenesis inhibitors
Tumour VEGF expression is signiﬁcantly higher in TNBC compared
with non TNBC presentations [65]. Studies identifying potential molecu-
lar markers of TNBC, such as VEGF [66], EGFR, Tyrosine Kinases [67], Src
[68], andmTOR [69], have impacted on the design of clinical trials, inves-
tigating targeted treatments in the space of angiogenesis inhibitors.
3.4.1. Anti-VEGF monoclonal antibody; bevacizumab
Bevacizumab, the anti-VEGF agent (Trade nameAvastin®Genetech/
Roche), has received controversial attention despite various promising
results from a variety of clinical trials. Speciﬁcally, there are multiple
Phase III trials looking at the efﬁcacy of bevacizumab in breast cancer,
with three trials assessing the drug as a ﬁrst line agent along with che-
motherapy in the TNBCmetastatic setting. These three trials are (1) the
E2100 study, (2) the Avastin & Docetaxel (AVADO) trial and (3) the
Regimens in Bevacizumab for Breast Oncology (RiBBOn)-1 trial [70].
In the E2100 trial, the risk of progression in ﬁrst-line TNBC pa-
tients was reduced by 51%whilst themedian PFS doubled (5.3 versus
10.6 months), when bevacizumab was added to paclitaxel. The
AVADO trial demonstrated a 47% reduction in disease progression
when bevacizumab was added to docetaxel in the TNBC subgroup.
However, there did not appear to be any clear beneﬁt in the RiBBOn-1
trial when bevacizumab was added to chemotherapy regimens.
Similarly, on TNBC subgroup analysis (N = 159), patient im-
provements were observed in the second line setting only in the
phase III RiBBOn-2 trial, demonstrating a 51% reduced risk of disease
progression and a doubling of median PFS among women treated
with the bevacizumab combination, compared with women treated
withchemotherapy alone [2.7 versus 6.0 months; HR = 0.49 (95%
CI 0.33–0.74), P = 0.0006]. There was also a trend towards improved
survival [median, 17.9 versus 12.6 months; HR = 0.624 (95% CI
0.39–1.007), P = 0.0534].
In the neo-adjuvant setting, two studies addressing the role of
bevacizumab are the GeparQuinto [71] and the National Surgical Adju-
vant Breast and Bowel Project 40 (NSABP)-B40 [72] trials, where this
anti-VEGF agentwas combinedwith neoadjuvant anthracycline–taxane
chemotherapy. In the TNBC subgroup, the two studies showed the op-
posing results. Speciﬁcally, GeparQuinto demonstrated a statistically
signiﬁcant improvement in pCR rates (N = 663; 39.3% versus 27.9%,
P = 0.003) for patients receiving bevacizumab compared with chemo-
therapy while, The National Surgical Adjuvant Breast and Bowel Project
(NSABP)-B40 showed no improvement of pCR rates. (N = 479; 51.3%
versus 47.3%, P = 0.44). The differing clinical outputs in the results
from these two trials might possibly reﬂect variations in how HER2-
negativity was deﬁned in the patient groups treated in the trials and
in the therapy regimens they received [73]. Longterm DFS and OS re-
sults are not yet available for these two studies. However, the potential
use of these anti-VEGF drugs in the treatment of early TNBCwill become
clearer as further results become available from the GeparQuinto and
(NSABP)-B40 in addition to the ongoing Bevacizumab Adjuvant Thera-
py in TRIple negative Breast Cancer (BEATRICE) Phase III trial.
In 2010, the FDA re-addressed the efﬁcacy of the drug, Avastin®
(bevacizumab) for the treatment of women with breast cancer, due to
its reported side effects/safety concerns such as thromboembolic
events, gastrointestinal perforation, wound healing complications,
haemorrhage, hypertensive crisis, nephrotic syndrome, congestive
heart failure and neutropenic sepsis. The FDA gradually removed breast
cancer for the use of Avastin® due to these concerns and on November
18, 2011, the Food and Drug Administration (FDA) Commissioner,
Margaret Hamburg revoked the agency’s accelerated approval of the
breast cancer indication for bevacizumab (Avastin® (bevacizumab)
made byGenentech). The Oncology Drugs Advisory Committee rejected
Genentech’s appeal based in part on themodest risk-beneﬁt ratio of this
agent in the overall population [74].
In 2011, Ranpura et al., published a meta-analysis in JAMA,
highlighting the adverse side effects of bevacizumab, showing that
when added to chemotherapy regimens, particular taxane and plati-
num drugs. Specifcally bevacizumab was associated with an increased
risk of fatal adverse events (FAEs), compared to using chemotherapy
alone [75]. Moreover, a total of 10,217 patients with a variety of ad-
vanced solid tumours from 16 randomised controlled trials (RCTs)
were included in the analyses. The overall incidence of fatal adverse
events with bevacizumab was 2.5% (95% CI, 1.7%-3.9%), with haemor-
rhage (23.5%), neutropenia (12.2%), and gastrointestinal tract perfora-
tion (7.1%), being the most common. Bevacizumab used for metastatic
breast cancer has also not been shown to provide a patient beneﬁt in
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terms of delay in tumour growth that would justify its serious and
potentially life-threatening risks. Therefore, there is currently no ev-
idence that the use of bevacizumab will either help women with
breast cancer live longer or improve their quality of life. This decision
involves bevacizumab’s use in combination with paclitaxel for
patients who have not been treated with chemotherapy for HER2
negative metastatic breast cancer. This indication has now been
removed from bevacizumab's product labelling.
3.5. Epithelial growth factor receptor (EGFR) inhibitors
The epidermal growth factor receptor (EGFR) is a member of the
ErbB family of receptors, a subfamily of four closely related receptor
tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3)
and Her 4 (ErbB-4).
3.5.1. Anti-EGFR monoclonal antibody; cetuximab
In patients with metastatic TNBC, a cetuximab plus cisplatin combi-
nation (BALI-I Trial) has demonstrated an overall better response rate
of 20%when compared to a 10% overall better response ratewith cisplat-
in alone [76]. Cisplatin plus cetuximab also resulted in longer PFS
compared with cisplatin alone (median, 3.7 v 1.5 months) with a
corresponding median OS of 12.9 versus 9.4 months. Common grade 3/
4 adverse events included acne-like rash, neutropenia, and fatigue. How-
ever, the BALI-I trial failed to reach its primary endpoint, namely the
overall response rate, despite apparently doubling it, compared to the
single regimen. This combination also appears to lengthen PFS and OS.
There was also a concern of toxicity such as diarrhoea when cetuximab
was added to chemotherapy such as carboplatin and irinothecan despite
an increased overall response rate in the TNBC subset of O’Shaughnessy’s
phase II trial [77]. Analysis of two randomised trials has shown that basal
like breast cancer patients lacking PTEN and alpha basic crystalline, pref-
erentially respond to cetuximab treatment [78]. Therefore, the potential
efﬁcacy of anti-EGFR strategies needs further investigation with further
trials such as those investigating combinations of cetuximab with
the non-taxane anti-tubulin agent, ixabepilone in both the early
(NCT01097642) and advanced (NCT00633464) settings.
3.5.2. EGF/Src tyrosine kinase inhibitors
Of the multiple-tyrosine kinase inhibitors, dasatinib, sunitinib
and neratinib have been studied in a setting where patients have al-
ready previously received heavy doses of standard chemotherapy [79].
Dasatinib, which has activity in haematologymalignancies and prostate
cancer, has been shown to inhibit the growth of TNBC cell lines in vitro
when used in combinationwith standard chemotherapy such as cisplat-
in andwhen used as a single agent [68]. However, a Phase II clinical trial
of women with locally advanced or metastatic TNBC showed a clinical
beneﬁt rate of only 9.3%when dasatinib was used as a single agent [80].
In relation to sunitinib, this tyrosine kinase inhibitor was not recom-
mended to be used in combination with doxetaxel in patients with
newly diagnosedHER2negative advanced or in patientswithmetastatic
breast cancer following a Phase III trial [81]. Like bevacizumab, sunitinib
is increasingly regarded as being ineffective in breast cancer [82].
For neratinib, the NCT01111825 Phase I/II trial is currently investigat-
ing its efﬁcacy in combination with the mTOR Inhibitor temsirolimus,
both in the metastatic TNBC and metastatic HER2 ampliﬁed setting.
The primary outcome is to estimate the maximum tolerated dose with
safety and efﬁcacy as secondary outcomes. Recruitment is through the
Memorial Sloan-Kettering Cancer Centre group and December 2015 is
the estimated completion for this trial.
The tyrosine kinase phosphatase, PTPN12, acts by inhibitingmultiple
oncogenic tyrosine kinases, including HER2 and EGFR and appears to be
mutated in 5% of TNBCs and absent from as many as 60% [83]. PTPN12
exhibits tumour suppressor actions when reintroduced into breast
cancer cells devoid of the enzyme [83]. Sunitinib and lapatinib might
therefore have beneﬁcial activity against these tumours. Phase 1/2
clinical trials should commence to determine whether FDA approved
tyrosine kinase inhibitors are effective in patients with PTPN12-
deﬁcient TNBC tumours. The possibility of a clinical trial with sunitinib
and crizotinib, two drugs that are FDA-approved andmarketed by Pﬁzer
is being explored by the Stand up to Cancer Breast Cancer Dream Team.
3.6. mTOR inhibitors
The serine-threonine kinase mammalian target of rapamycin
(mTOR) promotes protein translation, angiogenesis, proliferation and
migration [84]. Moreover, inhibiting mTOR’s mediated PI3K/Akt signal-
ling pathway abolishes cellular proliferative responses and causes cell
cycle arrest. As PI3K/Akt overactivity has been identiﬁed in a number
of breast cancers [69], rapamycin and its analogs temsirolimus, everoli-
mus, and deforolimus, are undergoing clinical evaluation in TNBC treat-
ment [85]. The mesenchymal subgroup of TNBC may beneﬁt from a
treatment targeting and inhibiting mTOR as the aggressive metaplastic
and claudin-low type is enriched in epithelial-mesenchymal transition
and stem-cell like features which make them more chemoresistant
than the luminal & basal subtypes [86].
In relation to the efﬁcacy of everolimus, the addition of this mTOR
inhibitor to standard chemotherapy did not signiﬁcantly improve path-
ological pCR rates in a phase II neoadjuvant trial of 50 TNBC patients [87]
with another neoadjuvant trial in progress (NCT00930930). Ongoing
studies investigating the use of everolimus in the treatment of advanced
TNBC are being investigated in the NCT01272141, NCT01111825 and
NCT00827567 trials. Speciﬁcally, NCT01272141 is looking at the combi-
nation of lapatinib, a dual role HER2/ EGFR inhibitor and everolimus in
locally advanced or metastatic TNBC. NCT01111825 is addressing the
role of temsirolimus plus neratinib in patients with either metastatic
HER2-ampliﬁed or TNBC, while NCT00827567 is examining the use of
everolimus as a single agent in metastatic TNBC.
The PTEN phosphatase, which inhibits the pro-growth PI3K/Akt
pathway, is lost in the majority of TNBC tumours, particularly African-
American and Hispanic patients [88]. PTEN loss is associated with
reduced disease-free survival, but might also render these tumours
susceptible to PI3K/Akt inhibitors.
The TNBC cell lineMDA-MB 435with PTEN deﬁciency has shown in-
creased sensitivity to mTOR inhibition [89], while Steelman et al., 2008
also demonstrated that suppression of PTEN function in theMCF 7 non-
TNBC breast cancer cell line, also increased sensitivity to the mTOR
inhibitor rapamycin [90]. Overexpression of S6K1 and expression of
phosphorylated Akt could be predictors of rapamycin sensitivity in
breast cancer patients with changes in cyclin D1 levels providing a
potential pharmacodynamic marker of response to rapamycin [91].
3.7. Androgen inhibition
Gucalp et al., 2010 have shown that androgens, through stimulating
the androgen receptor can induce proliferative changes in breast cancer
cell lines and promote tumourigenesis in animalmodels [92]. Androgen-
enhanced growth of the cell line MDA-MB-453 which has the same
biomarker phenotype as TNBC, is known to be ER-independent and
AR-dependent [93]. Intriguingly, 10%–35% of TNBC express androgen re-
ceptors [94]. Moreover, it has been suggested that a subset of TNBC cases
may beneﬁt from the addition of androgen blockade to their therapy
[95]. Bicalutamide, a nonsteroidal competitive androgen inhibitor, has
been used in the treatment of advanced prostate cancer, but until recent-
ly [96], its anticancer effects had not been clinically tested in women.
Speciﬁcally, the NCT00468715 is an ongoing clinical trial evaluating
the use of bicalutamide in the treatment of 65 women with ER/PR-
negative, AR-positive metastatic breast cancer with results presented at
the 2009 ASCO Breast Cancer Symposium. Clinically, bicalutamide was
well-tolerated and preliminary analyses have demonstrated disease
stabilisation in ER/PR negative, AR positive tumours with AR inhibition
[96].
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3.8. HDAC inhibitors
Other possible novel targeted therapies for TNBC include HDAC
(histone deacetylase inhibitors) inhibitors, such as vorinostat which
suppress cancer-cell proliferation by inducing cell-cycle arrest and/or
apoptosis [97]. A paper published in Cancer Letters discusses
vorinostat-induced apoptosis in the TNBC cell line MD-MBA-231 and
the role of the p38 MAP kinase in the suppression of cancer growth.
Interestingly, knockdown of p38 MAP kinase was associated with
decreased caspase-3 cleavage. This is of note as cleaved caspase 3
plays a role in autophagy by regulating the extracellular export of
autophagic vacuoles; an alternative cellular fate [98,99].
3.9. Immunotherapies and vaccines
TNBC patient outcome has been shown to correlate with the presence
of a tumour-immune inﬁltrate which suggests an area of great potential
for effective TNBC treatment [30]. Tumour-inﬁltrating lymphocytes
(TILs) play a role in controlling the clinical progression of various epithe-
lial cancers [100] with a recent review discussing the potential role that
the immune microenvironment plays in breast cancer development
[101].
The presence of an intense lymphocytic inﬁltrate may predict re-
sponse to neoadjuvant chemotherapy in breast cancer [102]. This was
proposed following an analysis of core biopsies from patients enrolled
in the GeparDuo and GeparTrio trial. In particular, the presence of
intratumoural lymphocytes and lymphocyte-predominant breast
cancers were associated with a 31% and 41% pathological complete re-
sponse (pCR) rates, respectively. In comparison, the pCR rates were
only 2% in patients without any lymphocytic inﬁltration [102]. At the
San Antonio Breast Cancer symposium in December 2013, Denkert
et al., presented ﬁndings from the GeparSixto trial (GBG 66), where
increased TILs predicted beneﬁt from addition of carboplatin to neoad-
juvant therapy for TNBC and HER2 positive breast cancer [103]. At the
same session, Adams et al., demonstrated the prognostic value of TILs
in two phase II randomised adjuvant breast cancer trials: Eastern
Cooperative Oncology Group (ECOG) 2197 and ECOG 1199 [104].
Given that TNBC has been recently categorised based on 6 molecular
subtypes [30], the immunomodulatory (IM) subtype, characterised by el-
evated expression of genes involved in T-cell function, immune transcrip-
tion, interferon (IFN) response and antigen processing, could beneﬁt from
immunotherapies. This would be a novel treatment strategy that may be
efﬁcacious to this subtype of TNBC. Interestingly, the immunomodulatory
subtype has been shown to overlap with medullary breast cancers, with
gene expression proﬁling showing that medullary breast cancer is a sub-
group of basal breast cancer displaying a prominent lymphocytic reaction
that is associated with a favourable prognosis [105,106].
Immune-checkpoint blocking antibodies and immune-stimulating
therapies might act synergistically when combined with chemothera-
peutic drugs. The adoptive transfer of chimeric antigen receptor
(CAR) -engineered T cells and tumour vaccines against cancer-testis
(CT) antigens, which appear highly expressed in TNBC as a result of
epigenetic changes, are also novel therapeutic strategies for the TNBC
immunomodulatory subtype [105].
The more aggressive claudin-low subtype often presents with an
intense immune cell inﬁltrate and stem cell features with epithelial–
mesenchymal transition features [107]. This subtype could therefore
also potentially be targeted by immunotherapy treatment [108].
3.10. Other novel signalling pathways
New sequencing technologies have also identiﬁed promising
therapeutic targets that alter apoptotic pathways. In one case, the
developmental signalling pathways Wnt/β-catenin, NOTCH and
Hedgehog have recently been shown to play an important role in
the pathogenesis and progression of TNBC with new potential thera-
peutic approaches inhibiting these pathways published [109].
JAK2 ampliﬁcations in TNBCs has also been shown to be associated
with a worse patient outcome and appear to be enriched in TNBCs.
Balko et al., at the 2013 San Antonio Breast Cancer Symposium present-
ed these ﬁndings and demonstrated that after neoadjuvant chemother-
apy, TNBCs enrichedwith this ampliﬁcationwere associatedwith a poor
prognosis, potentially identifying JAK2 inhibitors as novel and potential
treatments for TNBC [110]. Table 1 summarizes the current novel ther-
apies for TNBC.
3.11. N-acetyl cysteine (NAC)
It has been advocated that new cancer therapies should be developed
to target the metabolic inter-dependencies between epithelial cancer
cells and their surrounding stromal microenvironment. Moreover, it has
been suggested that cancer chemo-prevention and treatment should
focus on the development of new powerful anti-oxidants to minimise
oxidative stress, L-Lactate production and tumour stromal co-evolution.
The thiol anti-oxidant N-acetyl cysteine (NAC) behaves as an anti-
inﬂammatory due to NFKappaB inhibition and inhibits L-Lactate
production. Due to the fact that lactate has been shown to decrease
after chemotherapy or radiotherapy in animals [225], the monitoring
of this metabolite may be predictive of therapeutic response [226].
Clinically, N-acetyl cysteine (NAC) is already used in clinical practice
as an antidote for acute drug intoxication, in particular as a result of
Paracetamol poisoning with safe dosages and careful assessments of
its side effect proﬁle already known even at very high doses for long-
term treatments [227–229]. It also has a clinical role in inﬂammation
and acute respiratory distress [230].
However, the potential therapeutic use of NAC as an anti-cancer
agent is yet to be tried out in the clinical setting. Intriguingly, its ability
to negatively impact on the ability of cells to undergo senescence and or
autophagy and indeed resistance to anoikis, key cellular fates induced in
hypoxic environments, identiﬁes it as an attractive candidate to be used
in combination with our established adjuvant and neo-adjuvant treat-
ments in TNBC, an established and recognised hypoxic tumour with
an innately chemoresistant biology. Tables 2a and 2b summarise the
evidence to date that NAC could have a role as an antioxidant in cancer
and more speciﬁcally in TNBC.
4. Summary
Women presenting with triple negative breast cancer (TNBC) are
treated in the most part similarly in the adjuvant and neoadjuvant
Table 1
Summary of novel therapies for TNBC.
1. DNA Repair Mechanisms:
PARP Inhibitors – Olaparib, Iniparib, Veliparib
Platinum Salts – Carboplatin, Cisplatin
2. Non-Taxane Microtubule Stabilising Agents:
Ixabepilone
Eribulin
3. Angiogenic Inhibiton
Anti-VEGF Monoclonal Antibody – Bevacizumab (Avastin®)
4. EGFR/P13K/AKT/mTOR Signalling Pathways:
Anti-EGFR Monoclonal Antibody – Cetuximab
EGFR Tyrosine Kinase Inhibitors – Dasatinib, Neratinib, Sunitinib
mTOR Inhibitor – Temsirolimus, Everolimus, Deforolimus
5. Androgen Receptor inhibition
Bicalutamide
6. Histone deacetylase inhibition (HDAC)i
Vorinostat
7. Immunotherapies & Vaccines
8. Other Novel Signalling Pathways:
Hedgehog –monoclonal antibodies, small molecular inhibitors
NOTCH – monoclonal antibodies
WNT/β-catenin signalling – monoclonal antibodies, ligand receptor inhibitors
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setting to women who present with non-triple negative breast cancer.
This is despite thewidespread novel therapy strategies that are current-
ly being investigated in clinical trials. Due to varying histological sub-
types and molecular proﬁles within the heterogenous biology that is
TNBC, future treatment efﬁcacy and personalised treatment will need
to consider the uniqueness of these presentations in order to progress
a much needed individualised treatment strategy for these women.
5. Chemoresistance in TNBC
Chemoresistance can be attributable to the fact that although cyto-
toxic chemotherapy aims to kill cancer cells through apoptosis, tumour
cells have the ability to maintain viability following chemotherapeutic
exposure by undergoing alternative cellular fates such as cellular
senescence, therapeutic induced senescence (TIS) and autophagy.
Tumour environmental stresses such as starvation, hypoxia andDNA
damage have been shown to induce such fates as autophagy [111] and
senescence [112]. Both cellular fates being signiﬁcantly associated
with cancer cell survival and chemoresistance [113,114].
Genomic acknowledgment of at least 5 intrinsic breast cancer
subtypes coupled with at least 6–7 TNBC molecularly characterised
subtypes, makes it not surprising that the task of tailoring treatment
for breast cancer presentations a mineﬁeld [25,30].
However, adopting the approach of understanding the cellular fates
induced in TNBC and using this information to bypass their induction or
impede them from survival, has the potential to harness the efﬁcacy of
our current therapeutics more effectively. Despite the heterogeneity of
TNBC, if we can demonstrate that cellular fates and the tumour micro-
environment play a signiﬁcant role in chemoresistance, a potential
treatment target could be exploited for this tumour type by targeting
cellular fates and not speciﬁc signalling pathways.
5.1. Established mechanisms of chemoresistance in TNBC
Standard chemotherapy remains the backbone of systemic triple
negative breast cancer (TNBC) treatment even amidst advances in can-
cer treatment as neither hormonal therapy nor anti-HER2 agents are
efﬁcacious against TNBC due to the absence of a target [73]. At present,
the cure for cancer continues to escape oncologists due in a large part to
chemoresistance, which accounts for 90% of drug failures in metastatic
cancers [115]. Fig. 1 demonstrates six mechanisms of chemoresistance
in TNBC that are discussed in detail in this section namely, 1) APC
transposrters, 2) β-tubulin III, 3) mutations in DNA repair enzymes
such as topoisomerase II andDNAmismatch repair enzymes, 4) alter-
ations in genes involved in apoptosis, 5) ALDH1 and glutathione
(GSH)/Glutathione-S-transferase (GST) and 6) NF-ϰB signaling
pathways.
5.1.1. ABC transporters
One proposed method of chemoresistance involves ATP-binding
cassette (ABC) transporters found in a subpopulation of cancer stem
cells (CSCs), called side population (SP) cells [116]. Efﬂux of chemother-
apeutic drugs by SP cells has been linked to the ABC transporter
expressed in these cells. Three ABC transporters in particular have
been extensively studied in TNBC namely (a)multidrug-resistant
protein-1 (MRP1)which confers resistance to agents such as vinca alka-
loids, anthracyclines, and high-dose methotrexate but not paclitaxel or
mitoxantrone [117], (b) breast cancer resistance protein (ABCG2)
[118–120]which is responsible for the efﬂux of drugs such as doxorubi-
cin, and (c) the P-glycoprotein (MDR1) pump which pumps a wide
array of chemotherapeutics out of cancer cells, including paclitaxel
[115]. Speciﬁc inhibitors of ABC transporters are currently being tested
as a means for overcoming this chemoresistance along with non-
speciﬁc methods such as nanodiamond conjugation of chemotherapeu-
tic drugs to impair efﬂux through MDR1 overexpressing cells.
5.1.2. Overexpression of β-tubulin III subunit induces paclitaxel resistance
Tomassi et al., 2007 and Paradiso et al., 2005 have found that in
advanced breast cancer, βIII overexpression correlated with paclitaxel
resistance and progression of disease in patients given ﬁrst-line pacli-
taxel chemotherapy [121,122].
5.1.3. Mutations in DNA repair enzymes and enzymes altering drug
sensitivity
Reduced levels of expression or function of topoisomerase II, an
enzyme critical in DNA replication and repair, have been shown to
lead to chemoresistance to drugs such as the anthracyclines and
epipodophyllotoxins [123,124]. Chemoresistance may also arise from
aberrant DNA mismatch repair enzymes that function to repair DNA
damage from various chemotherapeutics such as alkylating agents,
platinum compounds, and anthracyclines. Fedier et al., 2001 have
further shown that there is a correlation between the loss of DNA-
mismatch repair proteins MSH2 and MLH1, and the associated micro-
satellite instability genotype coupled with resistance to topoisomerase
II inhibitors (epirubicin), doxorubicin, and mitoxantrone [125].
5.1.4. Alterations in genes involved in apoptosis
Alterations in genes regulating apoptosis (p53, caspase-3 s, bcl-2,
bcl-x) have been linked with chemoresistance to various chemothera-
peutics such as cyclophosphamide, doxorubicin, methotrexate, ﬂuoro-
uracil, and tubulin inhibitors [126–130].
5.1.5. Drug inactivation/detoxiﬁcation as a mechanism of chemoresistance
Overexpression of ALDH1A1 andALDH3A1have been shown to result
in greater inactivation of cyclophosphamide leading to chemoresistance
[131]. Moreover, increased glutathione and glutathione-S-transferase ac-
tivity results in increased breakdown of alkylating agents and cisplatin
thereby increasing resistance to these compounds [132]. Lastly, polymor-
phisms in the cytochrome P450 system (namely CYP3A4 and CYP2C8)
have been associated with highly basal enzymatic activity which may
also contribute to chemoresistance [133].
Table 2a
Evidence that N-acetyl cysteine (NAC) can act as an anti-cancer agent.
1. NAC induces p53-dependent apoptosis, has anti-tumour activities and has been
shown to be cancer chemo preventitive in clinical studies, with promise in
preventing tumour progression [229,231].
2. Treatment with thiol-containing antioxidants (such as NAC) has the potential to
preferentially induce apoptosis in preneoplastic and neoplastic human lung
ﬁbroblasts cells [232].
3. NAC is involved in the downregulation of VEGF expression, by limiting
hypoxia-induced transcription via hypoxia inducible factor-1-alpha (HIF1-α)
and repression of reactive oxygen species (ROS) [233]. Clinically this has
resulted in angiogenesis inhibition and thus reduction in tumour growth in
Kaposi Sarcoma [234].
Table 2b
Evidence that N-acetyl cysteine (NAC) has a role in targeting TNBC viability.
1. In comparison to the non-malignant breast cell line MCF-10A, it has been shown
in the TNBC cell line MB-MDA-231 in vitro, that redox controls progression of the
cell cycle suggesting that loss of redox control could drive aberrant cancer cell
proliferation [235]. Indeed redox regulation of cancer cells is emerging as a
potential therapeutic target in cancer [152].
2. Treatment of the TNBC cell line MDA MB 435 with NAC results in apoptosis and
reduction of microvascular density within the core of the tumour leading to
signiﬁcant tumour cell apoptosis/necrosis. This study demonstrated that NAC
promotes anti-angiogenesis resulting in endothelial apoptosis and vascular
collapse in the tumour [236].
3. NAC appears lethal in the BRCA1-deﬁcient TNBC cell lines HCC 1937 and MDA
MB 231. Immunostaining for MCT4 (a functional marker of hypoxia, oxidative
stress, aerobic glycolysis, and L-lactate efﬂux) [237] could be used as a
cost-effective biomarker to monitor the response to antioxidant therapy [238].
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5.1.6. Role of the NF-ϰB signaling pathway in chemoresistance
Treatment of breast cancer with disulﬁram and copper sensitises
breast CSCs to paclitaxel possibly by inhibiting constitutively active
NF-ϰB thereby alluding to the correlation between aberrant NF-ϰB
regulation and chemoresistance in TNBC [134].
5.1.7. KIF14-mediated AKT phosphorylation promotes chemoresistance in
TNBC
Singel et al., 2014 published that overexpression of KIF14 increased
chemoresistance to docetaxel in 34 cases of locally advanced TNBC.
Conversely KIF14 knockdown and chemical inhibition resulted in
lower levels of AKT phosphorylation and activity, leading to signiﬁcant
chemosensitisation when cells were treated with docetaxel. Important-
ly, phosphorylated AKT (pAKT) is an anti-apoptotic protein kinase in the
well-characterised prosurvival PI3K/Akt signaling pathway [135].
5.1.8. Molecular markers that could predict resistance to chemotherapy in
TNBC
Chekhun et al., 2009 have found that overexpression of
metallothioneins and glutathione-S-transferase were associated with
resistance to platinum salts while Zhou et al., 2011 reported that low
expression of the eukaryotic translation initiation factor 4E (eIF4E)
increased sensitivity to platinum salts [136,137]. As for taxane chemo-
therapy, overexpression of the microtubule-associated protein 2
(MAP2), interleukin 6 (IL6), matrix metalloproteinase 9 (MMP-9), and
low expression of inhibitor of tissue-plasminogen activation (t-PAI) in-
creased sensitivity [138,139] while overexpression of GRB-7 protein,
alpha B-crystallin, and P-glycoprotein conferred a chemoresistant
phenotype [140,141]. Resistance to PARP inhibitors was increased by
the overexpression of the multi-drug resistance efﬂux pumps (MDR
1,2) [142] and decreased by a deﬁciency of BRCA-1, BRCA-2, XRCC2,
and XRCC3 genes [143]. Conversely, the restoration of function of the
tumour suppressor gene BRCA-1 led to an increased chemoresistance
against PARP inhibitors [142].
Lastly, the low expression of the zinc-ﬁnger enhancer binding pro-
tein ZEB-1 increased sensitivity of TNBC cells to bicalutamide [144].
5.2. Selective resistance of cancer stem cells (CSCs) to chemotherapy
Treatment of TNBC with chemotherapeutics such as taxanes is
initially very effective in most patients. However, the majority of these
tumours will recur following chemotherapy treatment [145]. These re-
current tumours are typically chemoresistant, and are associated with
a poor prognosis [146]. There is an increasing amount of evidence that
suggests that following treatment, a small population of cells survive,
with stem-like properties that may be responsible for tumour recur-
rence [147]. These cells have been termed cancer stem cells (CSCs).
CSCs are tumour cells with self-renewal properties that have the ability
form a recurrent chemoresistant tumour. Lapidot et al. provided early
evidence in 1994 of the existence of CSCs by identifying a subpopulation
of cells in acute myeloid leukaemia (AML) that were capable of initiat-
ing leukemic growth when introduced into severe combined immuno-
deﬁciency (SCID) mice [148].
Recent evidence suggests that chemoresistant populations of
cancer stem cellsmay be responsible for relapse in triple negative breast
cancer (TNBC). The TGF-β family of cytokines has been implicated in
CSCs. TGF-β1 and the TGF-β type 1 receptor (TGF-βR1) have been
shown to be over-expressed in a subpopulation of breast cancer cells
with CSC features. TGF-β induces epithelial-to-mesenchymal transition
(EMT) inmammary cells,which has been associatedwith tumour stem-
like properties in cells [149].
In 2013, Bhola et al. reported that following chemotherapy treat-
ment, TNBC biopsies showed an increase in RNA transcripts of genes
Fig. 1.Mechanisms of Chemoresistance in TNBC. (A) ABC transporters efﬂux chemotherapeutics out of cancer cells (B) Overexpression ofβ-tubulin III subunit induces paclitaxel resistance
(C) Mutations in DNA repair enzymes and enzymes altering drug sensitivity (D) Alterations in genes involved in apoptosis prevent chemotherapy-induced apoptosis (E) ALDH1 and
glutathione (GSH)/Glutathione-S-transferase (GST) mediate chemotherapeutic inactivation/detoxiﬁcation (F) Role of NF-ϰB signaling pathway in chemoresistance.
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associated with CSCs and TGF-β signalling. Treatment with paclitaxel
also increased TGF-β signalling and CSC properties in TNBC cell lines
and mouse xenografts [150]. This suggests that initial treatment may
form a subpopulation of cancerous cells with stem-like properties that
can regenerate a chemoresistant tumour.
However, Bhola et al. also reported that using the TGF-β type 1 re-
ceptor kinase inhibitor LY2157299 in combination with paclitaxel,
prevented re-establishment of tumours in TNBC xenografts in mice
[150].
In 2014, Samanta et al. published that treatment of human TNBC
cell lines with paclitaxel or gemcitabine resulted in an increase in
hypoxia-inducible factors (HIFs) expression and transcriptional activity.
This resulted in an enrichment of the CSCs population through
interleukin-6 and interleukin-8 signalling [151]. This indicated that
HIFs may be involved in acquired chemoresistance of breast cancer
stem cells.
This study also indicated that the administration of HIF inhibitors in
combination with paclitaxel or gemcitabine, overcame the CSCs resis-
tance to the chemotherapeutics, which lead to tumour eradication,
both in vitro and in vivo [151].
Both these studies show evidence that the treatment of TNBC with
current therapeutics may result in the formation of a subpopulation
of chemoresistant cancer cells with stem-like properties, that if not
eliminated are free to form a tumour that is not responsive to current
chemotherapeutics.
5.3. Tumour hypoxia’s role in TNBC chemoresistance
Breast cancer cells are subjected to a high level of oxidative stress,
both intra- and extra cellularly [152]. Moreover, it is known that TNBC
is associated with a more hypoxic phenotype possibly due to activation
of the mTOR pathway and HIF-1α stabilisation [153]. Fig. 2 is a refer-
enced illustration demonstrating the role that hypoxia plays in cellular
fates. Clinically, the fact that TNBC’s are amenable to ﬂuroeoxyglucose-
positron emission tomography (FDG-PET) scanning as a result of the
“Warburg effect” [154] also highlights their more hypoxic phenotype
(Table 3).
The term hypoxia describes the phenomenon of an inadequate sup-
ply of oxygen as a result of cells outgrowing their vasculature [155] be-
yond the size of several mm3. This compromises the cells biological
functions with a concomitant increase in compensatory glycolysis
[156]. Importantly, hypoxia is a key microenvironment associated
with the tumour milieu with this acidic setting compromising chemo-
therapeutic efﬁcacy due to the varying levels of oxygen present in the
tumour [157]. Moreover, a hypoxic tumour environment results in an
increase in cellular senescence [114,159] and therefore potentially
propagating a chemoresistance phenotype.
Clinically, evidence that TNBC tumours are more hypoxic than non-
TNBC histologies is presented in Table 3 by either an increased FDG
uptake and standardise uptake values (SUV) on PET/CT imaging or in-
creased Carbonic Anhydrase IX (CAIX) immunohistochemical assess-
ment on full face parafﬁn embedded (FFPE) TNBC clinical material.
TNBCs are amenable to FGP-PET scanning on account of the “Warburg
effect” [154] with one study addressing the use of 18F-FDG PET/CT as
an early assessment in TNBC during neoadjuvant chemotherapy to
identify patients who are unlikely to achieve a pathologic complete re-
sponse and are at a high risk of early relapse [160]. CAIX, is an accepted
marker for tissue hypoxia and has been shown to be associated with a
worse prognosis for patients with TNBC [161,162]. Recent evidence
shows that basal endoplasmic reticulum stress (ERS) is typically activat-
ed in TNBC and cooperates with hypoxia signalling to promote tumour
progression and relapse [163].
5.4. Cellular senescence
The term cellular senescence was ﬁrst discovered and the term
coined in aging human ﬁbroblasts by Hayﬂick and Moorhead in 1961
who observed an irreversible exit of the cells from the cell cycle.
Senescent cells, however, although initially having lost their prolifera-
tive capacity, maintain cellular viability and metabolic activity [112]
generating a senescent secretome called the SASP phenotype or senes-
cence associated secretory phenotype.
In relation to the role of cellular senescence in cancer, on the one
hand it can be regarded as a tumour suppressor mechanism for cells
[114], [135], [136], [138]
[167][178-180][182-183]
[172-177]
Fig. 2. The role hypoxia plays in cellular fates including references.
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in response to DNA damage, telomere attrition, oxidative stress, DNA
damage and other tumour-promoting insults [112] and indeed there
is evidence that the progression of malignant invasive tumours is
believed to arise from the evasion of senescence in the pre-invasive
precursor tumour [164]. Recent evidence however also implicates the
senescence pathway in breast carcinogenesis [165] through promoting
tumour progression by stimulating growth and transformation in
adjacent cells through the senescence associated secretory phenotype
(SASP) [166].
5.5. Hypoxia, senescence and stroma
Table 4 demonstrates the role hypoxia plays in determining cellular
senescence in cancer with clear conﬂicting views evident.
The contribution of the stromal component and the inter-
dependencies between tumour epithelial cells (TECs) and their stro-
mal environment, tumour associated ﬁbroblasts (TAF) in an oxygen
stressed /L-lactate rich environment has been identiﬁed as a key cancer
research area. This is new model of cancer metabolism, identifying the
role of aerobic glycolysis and L-lactate production in fuelling tumour
growth and metastasis [137].
Intriguingly, senescent cells produce considerable amounts of lac-
tate and play a key role in the tumour-stroma co-evolution. In relation
to the relevance of this to breast cancer, lower levels of lactate have
been observed in breast cancer patients with long-term survival
(≥5 years, survivors) compared to patients who died of cancer recur-
rence [174].
This novel hypothesis led by Professor Lisanti in Thomas Jefferson
University, Philadelphia is coined the “Reverse Warbung effect” as aero-
bic glycolysis takes place in stromal ﬁbroblasts, rather than epithelial
cancer cells. This group demonstrated that MCT4 immunostaining of
human TNBC micro arrays can be used to directly assess prognosis
[175]. MCT4 is a functional marker of hypoxia, oxidative stress, aerobic
glycolysis, and L-lactate efﬂux. High stromalMCT4 levelswere associated
with decreased overall survival (b18% survival at 10 years post-
diagnosis). In contrast, patients with absent stromal MCT4 expression
had 10 year survival rates of ~97%. Interestingly, epithelialMCT4 staining
demonstrated no prognostic value, suggesting that the tumour stroma
may represent a needed focus for targeted therapy.
Oxidative stress induced by the tumour epithelial cells (TECs),
results in increased levels of ﬁbronectin (FN) on the surface of adjacent
senescent tumour associated ﬁbroblasts (TAFs) [176]. Increased pro-
duction of FN is one of the most typical features of senescent cells
[177,178] and potentially is an antigenic determinant unique to cellular
senescence [179]. Intriguingly FN is differentially upregulated in TNBC
compared to Her2+, ER-PR- [180].This increased synthesis of FN is
mediated by TGF-α1 [176] which can stimulate p16 (INK4), a marker
of cellular senescence [181].
Mechanistically, reconstitution of p16 has been shown to increase
the expression of the FN receptorα5β1 on TECs [182].Moreover, elevat-
ed intracellular reactive oxygen species (ROS) produced by oxidatively
stressed mitochondria increases α5β1 expression on tumour epithelial
cells (TECs) [183]. When bound to extracellular matrix components
such as FN, α5β1 co-operates with growth factors to activate anti-
apoptotic signalling.
It has also been shown that with increasing age, the accumulation of
senescent cells alter the tissue architecture to the extent that it provides
a permissive environment of uncontrolled growth of adjacent premalig-
nant cells [184]. Moreover, ﬁbroblasts adjacent to malignant tissue in
contrast to those neighbouring the normal epithelium have been
found to be senescent [185] suggesting a possible role for their assess-
ment in identifying tumour free margins.
The role of epithelial versus stromal features of senescent cells in
predicting outcome for patients presenting with TNBC, irrespective of
the chemotherapeutic used or the individual subtype of TNBC, is a
potential area of research.
Table 3
Clinical published evidence that triple negative breast cancer (TNBC) is more hypoxic than non-TNBC histologies.
Hypoxia Appreciation Patient Numbers Details Reference
FDG-PET N = 88
TNBC = 29
ER+/PR+/HER2- = 59
TNBC tumours associated with enhanced FDG uptake, and detected
with very high sensitivity using FDG-PET imaging.
Basu et al., 2008 [154]
FDG-PET N = 41
TNBC = 22
Non-TNBC = 19
The degree of tumour FDG uptake correlated signiﬁcantly with
proliferation in women with TNBC, suggesting a potential role of
FDG-PET in monitoring treatment response for this group of women.
Tchou et al., 2010 [167]
FDG PET/CT N = 78
(Stage II / III Breast
Cancers)
FDG-PET/CTs were acquired before and after the ﬁrst cycle of
chemotherapy to evaluate early metabolic response. In TNBC, the
pre-chemotherapy standardised uptake value (SUV) was higher than
in non-TNBC.
Keam et al., 2011 [168]
18 F-FDG PET/CT N = 152
(Primary Breast Cancers)
High SUV levels were signiﬁcantly correlated with tumour size,
poorer grade, nuclear atypia, increased mitotic index, negative
hormone receptor status, high score of HER-2 expression, lymph
node metastasis, and IDC in comparison with invasive lobular
carcinoma.
Ueda et al., 2008 [169]
18 F-FDG-PET N = 91
(Invasive Ductal
Carcinomas)
High FDG uptake correlated with poor prognosis factors, such as
tumour invasiveness N2 cm, higher tumour grade, hormonal
receptor negativity, and triple negativity.
Kim et al., 2012 [170]
18 F-FDG–PET N/A 18 F-FDG–PET had a higher sensitivity for TNBCs than
oestrogen-positive and human epidermal growth factor receptor
2-positive tumours.
Dogan et al., 2012 [171]
Protein expression of CAIX and BRCA1 evaluated
by AQUA (Automated Quantitative Analysis)
Technology (IHC)
N = 619
TNBC = 111
Unselected Cohort = 508
CAIX was expressed in 7% of the unselected breast cancer cohort and
in 25% of the TNBCs and signiﬁcantly associated with the triple
negative phenotype. CAIX also associated with poor outcome.
Neumeister et al., 2012
[161]
FFPE Tissue Sections stained for various hypoxic
markers, including; HIF-1α, PHD1-3, and CAIX
CAIX Staining:
N = 456
Basal-like = 62
50% of basal-like tumours expressed HIF-1α, and more than half
expressed at least one of the PHD enzymes and FIH-1. Basal-like
tumours were nine times more likely to be associated with CAIX
expression. Patients with any CAIX-positive breast tumour
phenotype or CAIX basal tumours had a signiﬁcantly worse
prognosis than CAIX-negative tumours, partly attributable to an
enhanced hypoxic response.
Tan et al., 2009 [162]
Note:- FDG-PET= ﬂudeoxyglucose-positron emission tomography, SUV= standardised uptake value, SUV represents the ratio of the image derived radioactivity concentration found in
a selected part of the body at a certain time point. CAIX= carbonic anhydrase, HIF-1-α=hypoxia inducible factor, IDC= invasive ductal carcinoma, PHD= prolyl hydroxylase domain,
FIH = factor inhibiting hypoxia-inducible factor.
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5.6. Autophagy
Autophagy, type II programmed cell death, is an evolutionarily con-
served, self-degenerative process involved in protein and organelle
recycling and cellular homeostasis [186]. There are three types of
autophagy; macroautophagy [187], microautophagy [188] and chaper-
one mediated autophagy (CMA) [189]. Macroautophagy involves the
formation of a double-membraned structure in the cytoplasm (the
autophagosome), which grows and eventually fuses at either end thus
capturing themajority of cytoplasm and some organelles in the process.
This autophagosome then fuses with the lysosome for degradation
[151]. Microautophagy, on the other hand, refers to the direct transfer
of cytosolic components into the lysosome by invagination of the
lysosomal membrane and subsequent budding into vesicles within the
lysosome itself [152]. Chaperone mediated autophagy (CMA) uses a
different approach completely with speciﬁc selection and removal of
proteins with particular peptide sequence motifs that are recognised
by molecular chaperones, which then fuse with the lysosome via a
lysosome-associated membrane protein Lamp2a for selected removal
[151].
Autophagy appears to modulate both cell viability and death [190].
However, the role of autophagy in cell death is controversial. The
presence of autophagic vacuoles in dying cells may be interpreted in
one of two ways: either cells activate autophagy in an attempt to
survive, or autophagy is a part of the process of cell death [191].
Autophagy is often expressed at a basal level in cells representing its
role in the recycling of proteins and tissue homeostasis [192]. However,
in addition to the role of autophagy in protein quality control, this cellu-
lar fate mechanism also plays an integral role in cell survival during
cytotoxic stresses such as hypoxia, nutrient deprivation, DNA damage
and in response to chemotherapeutics and radiotherapy [193,194].
However, the overall role of autophagy in cancer is far more contro-
versial with its inhibition and induction both showing beneﬁcial and
negative effects of tumour cell survival [195–197].
In tumour cells the role of autophagy may depend on the type of
tumour, the stage of tumourigenesis and the nature and extent of the
insult [198]. Inhibiting cytoprotective autophagy or promoting type II
programmed cell death are mechanisms that could enhance the effects
of cytotoxic chemotherapeutics [195].
5.7. Autophagy and hypoxia
Autophagy provides the cell with an anaerobicmetabolicmechanism
which supplies the cell with the basic metabolic portfolio to survive dur-
ing oxidative stress or nutrient deprivation. It is also responsible for the
removal of ROS [199] and unfolded proteins generated during oxidative
stress and cellular aging [200].
The role of autophagy in an oncological setting has received much
attention, speciﬁcally coined as the “Autophagic Tumour-Stromal
Model” of cancer metabolism and tumour cell survival [201].
This model explains why angiogenesis inhibitors might not work,
and instead induce lethal tumour recurrence, and metastasis. This is
partially attributable to the fact that angiogenesis inhibitors drive
“hypoxia” in the tumour stromal micro-environment. Hypoxia, in turn,
drives oxidative stress and autophagy.
It has already been shown that paclitaxel induces autophagy in the
cell line A549 human alveolar adenocarcinoma. However, conversely,
inhibiting autophagy potentiates paclitaxel’s-mediated apoptotic effects
[202].
In vitro studies have also demonstrated that hypoxia protects
the TNBC cell line, MDA-MB-231 from paclitaxel-induced apoptosis
and concomitantly induced an autophagic response after 2 hours in
normoxic and hypoxic condition. Speciﬁcally, the mechanism of de-
creased apoptosis was studied using p62siRNA transfection, a protein
involved in autophagosome formation. These results demonstrated
that hypoxia diminishes paclitaxel-induced apoptosis in MDA-MB-231
cells via mTOR/JNK pathway [203].
Recently, a new form of autophagy has emerged known as
mitophagy, which is believed to play a very important role in cancer
cell survival [204], particularly in hypoxic regions of tumours. This is
supported by studies of models with monoallelic deletion of Beclin-1
showing increased cell death in these tumour regions [205]. Mitophagy
involves the selective removal of damaged mitochondria, subsequently
decreasing ROS and cytotoxic molecules of apoptosis and thus, promot-
ing cell survival [206,207]. Mitophagy is induced by BNIP3 whose ex-
pression in turn is regulated by hypoxia-inducible factor-1 (HIF-1)
expression or the Ras/raf/Erk pathway [207,208]. Ras mutated tumours
can therefore become very dependent on autophagic pathways, partic-
ularly mitophagy, through overactivation of autophagic pathways
such as Ras/Raf/Erk or indirectly through hypoxia-induced expression
of HIF-1. Due to the hypoxic nature of tumours, HIF pathways are of
great importance in tumour progression. Cells have been found to
adapt energy metabolism to hypoxic conditions through 4 main HIF-
mediated mechanisms: (1) COX4 subunit switching, (2) inhibition of
acetyl-CoA synthesis by activation of PDK1, (3) c-Myc repression
and inhibtion of mitochondrial biogenesis and the newer concept of
Table 4
The role hypoxia plays in determining cellular senescence in cancer.
Cellular Fate Determination
of Cellular Fate
Details/Results
Senescence Watson
et al., 2009 [114]
SA-β-gal PwR-1E benign prostate epithelial cells
and equivalently aged hypoxia-adapted
PwR-1E cells were used to identify the
phenotypic and epigenetic consequences
of chronic hypoxia in prostate cells.
The impact of chronic hypoxia (1% O2) on
cellular senescence was assessed by
β-galactosidase activity for both cell lines.
Increased levels of cellular senescence
were identiﬁed in the hypoxic population
of PwR-1E cells compared to their
normoxic counterparts.
Senescence
Hammond et al.,
2005 [172]
p53
Immunoblotting
RKO, 293 T, RCC4, and HCT116 cell lines
used.
HIF-1α protein accumulated with similar
kinetics at 0.2% and 2% oxygen. p53
protein accumulated in response to 0.02%
oxygen only. p53 accumulated in
response to hypoxia independently of
HIF-1α.
Accumulation of p53 correlated with
replication arrest.
Senescence
Welford et al.,
2011 [173]
N/A Reports conﬂicting evidence on the role of
hypoxia in senescence:
Excess O2 can lead to the production of
Reactive Oxygen Species (ROS) which can
promote senescence. Reduced O2 levels
(hypoxia) can reduce the amount of ROS.
Hypoxia leads to the stabilisation of HIF,
which impacts on many pathways that
can affect senescence:
HIF binding to Myc can induce p21
expression and inhibit CDC25C,
promoting cell-cycle arrest.
HIF controls several genes in the
senescence-associated secretory
phenotype (SASP) that can promote
senescence.
However, HIF also promotes glycolysis,
and can induce expression of TERT,
negatively regulating p53, both of which
are inhibitory to a senescent phenotype.
Note:- TERT = Telomerase reverse transcriptase, CDC25 phosphatases are important
regulators
of the cell cycle, Myc = transcription factor.
268 E.A. O’Reilly et al. / BBA Clinical 3 (2015) 257–275
mitochondrial autophagy, which as described above, decreases ROS re-
lease from damaged mitochondria thus promoting cell survival [206].
5.8. Autophagy inhibition & TNBC
Protein expression of the autophagy-relatedmicrotubule-associated
proteins, including beclin-1, light chain (LC) 3A and LC3B have been
shown to be the highest in TNBC cells compared to the other breast can-
cer subtypes, with the lowest expression in the stroma of TNBC [209].
High expression of LC3B is also associated with tumour progression
and poor outcome in TNBC [210] demonstrating its role as a potential
prognostic marker in TNBC.
Intriguingly cancer cell viability has also been shown to be reduced
through induction of non-apoptotic, non-autophagic cytoplasmic vacu-
olation death in TNBC cells through the expression of the LC3 protein
and p62/SQSTM1; a protein involved in autophagosome formation
[211].
Moreover, inhibition of autophagy has been identiﬁed as a potential
adjunctive strategy for enhancing the chemotherapeutic effect of pacli-
taxel. In addition, by inhibiting autophagy with the pharmacological
autophagy inhibitor chloroquine, a synergistic effect of enhanced
TNBC cell death both in vivo and in vitro was noted when used with
the endoplasmic reticulum stress aggravator (ERSA) compounds such
as the antiretroviral Nelﬁnavir, and the COX2 inhibitor Celecoxib [212].
Tables 5 and 6 summarise the relationship between hypoxia and the
fates of autophagy and apoptosis respectively in TNBC speciﬁcally.
6. Conclusion
Finding efﬁcacious treatments for TNBC is critical due to the fact that
thesewomen are treated, in themost partwith standard chemotherapy.
This approach does not tailor to the speciﬁc biology of TNBC and itsmo-
lecular subtypes. Even though the concept of standard chemotherapy in
breast cancer is becoming a thing of the past with a) oncotyping and
b) other molecular markers identifying hormone sensitive tumours
that gain no beneﬁt from chemotherapy, these do not however, apply
to patients with TNBC resulting inevitably in a signiﬁcant number of
women not responding to ﬁrst line treatment.
With this in mind and in order to improve patient outcome it is cru-
cial to establish a) what factors inﬂuence a patients’ individualised re-
sponse to chemotherapy and b) which factors may explain why some
patients fail to beneﬁt from standard ﬁrst-line chemotherapy, while
others achieve long-term remission.
In this regard, research speciﬁcally focused on interrogating the
mechanisms and ability of tumour cells to circumvent and bypass apo-
ptotic death mechanisms through adopting viable cellular fates such
as cellular senescence and cytoprotective autophagy is warranted. In
particular, targeting these non-apoptotic survival pathways has the po-
tential to enhance the chemotherapeutic efﬁcacy of our current artillery
of drugs for women presenting with TNBC.
6.1. Summary
In speciﬁcally targeting the survival mechanisms that cancer cells
can use to bypass death through apoptosis, viable cellular fates such as
cellular senescence and cytoprotective autophagy could potentially be
a target for impedance or manipulation and thus increase the death
rate of cancer cells. Importantly, both these cellular fates are induced
in tumour hypoxia, a key tumour microenvironment associated with
TNBC and integral to chemoresistance. In the case of senescence, anti-
oxidants such as NAC in combination with standard chemotherapuetics
hold potential in eradicating these metabolically active SASP secreting
cells, as do the combinatorial use of mTOR inhibitors or glycolytic
inhibitors such as rapamycin to promote terminal autophagy. Such ap-
proaches are worth serious consideration and may offer more potential
than attempts to ﬁnd speciﬁc tailored therapies for themyriad of genet-
ic and epigenetic changes and tumour cell populations unique to each
patient’s tumour and tumour microenvironment.
Table 5
The role hypoxia plays in determining the cellular fate autophagy.
Pike et al., 2013 [213] MCF7, MDA-MB-231, HCT116, HEK293,
MEF3T6, T47D, and HeLa cell lines
ULK1 Autophagy-initiating kinase ULK1 (UNC51-like kinase 1) is a direct transcriptional target of
ATF4 (activating transcription factor 4), which drives the expression of ULK1 mRNA and protein
in severe hypoxia. ULK1 is required for autophagy in severe hypoxia and ablation of ULK1 causes
caspase-3/7-independent cell death.
ULK1 expression is associated with a poor prognosis in breast cancer.
Salem et al., 2012 [214] Human hTERT-immortalized
ﬁbroblasts
MDA-MB-231 cell
HIF-1α shBRCA1 ﬁbroblasts displayed an elevated growth rate. Using immunoﬂuorescence and
immunoblot analysis, shBRCA1 ﬁbroblasts demonstrated an increase in markers of autophagy
and mitophagy. Most notably, shBRCA1 ﬁbroblasts also displayed an elevation of HIF-1α
expression.
Using xenografts demonstrated that shBRCA1 ﬁbroblasts induced an approximate 2.2-fold
increase in tumour growth when co-injected with MDA-MB-231 cells into nude mice.
Sotgia et al., 2011 [215]
Witkiewicz et al.,
2011 [216]
Malignant melanoma
44 cases: 24 lymph node metastasis, 20
primary tumours.
IHC stained for Cav-1
stromal
Cav-1
Coupling of metabolism between epithelial cells and surrounding stroma between oxygenated
and hypoxia compartments. Increased autophagy/mitophagy in the stroma drives metabolism in
the epithelial cells.
Ammonia production in the epithelial cells then drives autophagy in stroma to promote this cycle.
Loss of Cav-1 in stroma leads to early recurrence, metastasis, drug resistance and poor clinical
outcome.
Azad et al., 2008 [217] Two glioma cell lines (U87, U373).
Two breast cancer cell lines
(MDA-MB-231, ZR75).
One embryonic cell line (HEK293).
BNIP3 Under normoxic conditions, all ﬁve cell lines displayed etoposide-induced apoptosis whereas
hypoxia failed to induce these apoptotic responses
BNIP3 overexpression induced autophagy, while expression of BNIP3 siRNA or a
dominant-negative form of BNIP3 reduced hypoxia-induced autophagy
Tan et al., 2007 [218] Normal breast tissue n = 11
DCIS n = 81
IDC n = 251
BNIP3
and
HIF1a
Stained for BNIP3 and hypoxia-inducible factor-1alpha.
BNIP3 expression was signiﬁcantly up-regulated in the cytoplasm of DCIS and invasive
carcinoma compared with normal breast
Nuclear BNIP3 expression was associated with smaller tumour size, low tumour grade (P= 0.005),
and oestrogen receptor positivity in invasive tumours
Nuclear BNIP3 expression in DCIS was associated with a 3-fold increase in recurrence and a shorter
disease-free survival
No association between HIF-1α and BNIP3 expression
Note: ULK= autophagy-initiating kinase, a homologue of yeast ATG1,CAV1= caveolin 1 leads to oxidative stress, BNIP3= Bcl-2 and nineteen-kilodalton interacting protein-37 and is a
member of the Bcl-2 protein family.
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